vTv Therapeutics (NASDAQ:VTVT) Upgraded by Wall Street Zen to “Buy” Rating

by · The Cerbat Gem

Wall Street Zen upgraded shares of vTv Therapeutics (NASDAQ:VTVT – Free Report) from a hold rating to a buy rating in a research report sent to investors on Saturday.

VTVT has been the topic of a number of other research reports. Zacks Research upgraded vTv Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday. Roth Mkm assumed coverage on vTv Therapeutics in a report on Thursday, January 22nd. They issued a “buy” rating and a $58.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of vTv Therapeutics in a report on Friday, March 27th. BTIG Research restated a “buy” rating and issued a $49.00 price target on shares of vTv Therapeutics in a report on Wednesday, March 11th. Finally, Evercore assumed coverage on vTv Therapeutics in a report on Thursday, March 12th. They issued an “outperform” rating and a $44.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $53.00.

View Our Latest Report on vTv Therapeutics

vTv Therapeutics Trading Down 7.1%

NASDAQ VTVT opened at $35.69 on Friday. The business’s 50 day moving average is $35.95 and its two-hundred day moving average is $34.08. vTv Therapeutics has a 12-month low of $14.00 and a 12-month high of $44.00. The stock has a market capitalization of $140.62 million, a price-to-earnings ratio of -38.38 and a beta of 0.26.

vTv Therapeutics (NASDAQ:VTVT – Get Free Report) last released its earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $1.44. The business had revenue of $36.84 million for the quarter, compared to analyst estimates of $20.00 million. Equities analysts forecast that vTv Therapeutics will post -2.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On vTv Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of VTVT. Goldman Sachs Group Inc. acquired a new stake in shares of vTv Therapeutics during the fourth quarter worth $221,000. Geode Capital Management LLC boosted its holdings in shares of vTv Therapeutics by 84.3% during the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after purchasing an additional 12,896 shares during the last quarter. 683 Capital Management LLC acquired a new stake in shares of vTv Therapeutics during the fourth quarter worth $731,000. Finally, Baker BROS. Advisors LP boosted its holdings in shares of vTv Therapeutics by 52.4% during the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock worth $3,463,000 after purchasing an additional 51,000 shares during the last quarter. Hedge funds and other institutional investors own 17.51% of the company’s stock.

vTv Therapeutics Company Profile

(Get Free Report)

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.

Recommended Stories